"An accurate prognosis is equally important for those whose likelihood of success is quite high and for those whose chances are much lower than age-based predictions," Dr. James Grifo, Program Director of the New York University Fertility Center and Director of the Division of Reproductive Endocrinology and Professor of Obstetrics and Gynecology at the NYU School of Medicine. "Predicting the chances of IVF success for each patient may also support physicians in refining clinical protocols to improve care."
"More accurate personalized prognoses of potential live birth outcomes with IVF can guide both patients and their physicians with treatment decisions," said Dr. Gedis Grudzinskas, Consultant in Infertility and Gynaecology at 92 Harley Street, London Bridge Hospital, Princess Grace Hospital and Woodlands Health Centre, London, UK, and Editor of Reproductive Biomedicine Online, an international journal devoted to biomedical research on human reproduction.
Enhancing Care through Predictive Analytics
Previously, advanced predictive modeling that is rigorously validated was not accessible to patients and the broader medical community. Univfy has integrated these research processes with proprietary, analytics-powered platforms to deliver scientifically validated predictive information via a user-friendly interface to patients and providers. The Univfy platforms can also serve point-of-care prognostics or administrative needs in other areas of healthcare, outside of reproductive medicine.Univfy offers complimentary and confidential analysis to any clinic interested in learning how closely their patient-specific success rates compare to the Univfy PreIVF model. This analysis is feasible even for small or mid-size fertility clinics. Based on its proven model, Univfy offers two prediction tests for consumers: the Univfy PreIVF for women considering IVF for the first time, and the Univfy PredictIVF for women who have had IVF and are considering another IVF treatment. Both are online tests that patients complete in the privacy of their own home by simply entering their own individual health data. The tests are also available for use in physician offices via Univfy's clinic platform through a business-to-business model. Semi-customization of prediction tests is also available upon request. The complete study results will be available electronically on March 21, 2013 at Science Direct and Fertility and Sterility at www.fertstert.org, and will also be available in the June, 2013 issue of Fertility and Sterility. For more information about Univfy's IVF prediction tests, visit www.univfy.com. About Univfy Inc.: Los Altos, Calif.-based Univfy Inc. is a privately-held company specializing in the development and integration of powerful statistics and computation with an innovative web platform to bring evidence-based, personalized, prediction of treatment success to fertility patients and their health care providers. The company was founded in 2009 by former Stanford University faculty Mylene Yao,M.D. and Stanford University professor Wing Wong, Ph.D. For more information, visit www.univfy.com. SOURCE Univfy Inc.